Contraceptives Market to Reach US$ 62 Billion by 2033

According to market research and competitive intelligence firm Fact.MR, the size of the worldwide contraceptives market is anticipated to grow from US$33 billion to US$62 billion by the end of 2033. Strong government initiatives and campaigns for women's and children's health are driving the market.

The use of contraceptive techniques is being encouraged by robust government programs and initiatives for women's and children's health. Women who do not want to utilize hormonal intrauterine devices (IUDs) because of the possibility of negative effects tend to prefer copper devices.

𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗮 𝗙𝗿𝗲𝗲 𝗦𝗮𝗺𝗽𝗹𝗲 𝗖𝗼𝗽𝘆 𝗼𝗳 𝘁𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁 -https://www.factmr.com/connectus/sample?flag=S&rep_id=4719

Contraception is a method of preventing pregnancy that involves the use of a device or medicine. It is sometimes called birth control or fertility control. The use of contraception prevents pregnancy during sexual activity. The most effective method of contraception depends on the individual's circumstances and health. Contraceptive methods or drugs interfere with the normal sperm-ovum fertilization process in order to prevent conception.

Country-Wise Insights

Why is the United States a Lucrative Market for Contraceptive Manufacturers?
“Rising Teenage Pregnancy Rates”

The United States is one of the leading producers and consumers of contraceptives globally. The market is expected to see substantial growth due to advanced medical infrastructure, widespread acceptance of contraceptive methods, and established distribution networks.

With a large proportion of the female population in the country being of reproductive age, the growing rate of teenage pregnancies is also contributing to the market's expansion.

Competitive Landscape

Leading companies in the contraceptive market are focusing on research and development to introduce innovative contraceptive devices that adhere to safety standards and minimize environmental impact. These top providers are also expanding through acquisitions and collaborations with other businesses, while continuously improving product quality.

For example, in 2021, Cooper Surgical, Inc. acquired Generate Life Sciences, enhancing its reproductive health portfolio. That same year, Clue launched a digital birth control method that offers ovulation predictions based on statistical data. Pfizer Inc. introduced Sayana Press, the first injectable contraceptive for women in the U.K., and is conducting studies to evaluate the potential of levonorgestrel and Ethinyl estradiol as oral contraceptives. Meanwhile, Merck & Co., Inc. provides a wide range of contraceptive options, including combined oral pills, vaginal rings, intrauterine devices, and sub-dermal implants, with popular products like Cyclessa, Desogen, NuvaRing, Implanon, and Nexplanon. Cipla manufactures Crisanta, an oral contraceptive containing Drospirenone, which prevents fertilization and induces hormonal changes to prevent pregnancy.

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com